logo

BRTX

Biorestorative·NASDAQ
--
--(--)
--
--(--)
3.09 / 10
Netural

BRTX's fundamental score is 3.1/10, reflecting poor financial health. Key concerns include negative year-over-year revenue growth (-4.92%) and a high days sales outstanding (80.10), both of which are red flags. However, the interest coverage ratio (15.48) provides some relief, suggesting the company can service its debt. Overall, the fundamentals warrant a guarded outlook.

Fundamental(3.09)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-5.52
Score1/3
Weight10.53%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value-4.92
Score1/3
Weight-1.53%
1M Return-0.79%
Days sales outstanding
Value80.10
Score0/3
Weight-9.27%
1M Return-5.18%
Profit-MV
Value0.46
Score2/3
Weight20.92%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight20.94%
1M Return8.45%
PB-ROE
Value0.85
Score2/3
Weight26.09%
1M Return9.14%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-2.09%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-4.92
Score1/3
Weight-1.48%
1M Return-0.76%
Asset-MV
Value-0.50
Score1/3
Weight15.31%
1M Return6.68%
Cash-MV
Value-0.07
Score2/3
Weight20.57%
1M Return8.41%
Is BRTX undervalued or overvalued?
  • BRTX scores 3.09/10 on fundamentals and holds a Fair valuation at present. Backed by its -205.51% ROE, -3304.77% net margin, -0.86 P/E ratio, 4.18 P/B ratio, and -2.10% earnings growth, these metrics solidify its Netural investment rating.